Zentalis Pharmaceuticals (ZNTL) Cash from Investing Activities (2019 - 2026)

Zentalis Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 25.85% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $121.2 million, a 22.08% decrease from a year earlier, with the FY2025 full-year figure at $131.6 million, down 25.45% from the prior year.
• Cash from Investing Activities fell to $30.0 million in Q1 2026 per ZNTL's latest filing, from $32.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $72.9 million in Q2 2023 and bottomed at -$142.1 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is $30.4 million (2025), against an average of $10.6 million.
• Across the five-year window, Cash from Investing Activities plunged 686.73% in 2023 and soared 176.75% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$11.9 million in 2022, then plunged by 253.62% to -$42.1 million in 2023, then jumped by 176.75% to $32.3 million in 2024, then advanced by 0.51% to $32.4 million in 2025, then decreased by 7.5% to $30.0 million in 2026.
• Per Business Quant, the three latest ZNTL Cash from Investing Activities figures stand at $30.0 million (Q1 2026), $32.4 million (Q4 2025), and $28.3 million (Q3 2025).